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Summary: The purpose of this study was to evaluate the use of the biologic immune activation markers neopterin
and ß2-microglobulin in monitoring human immunodeficiency virus (HlV)-positive patients without acquired immu-
nodeficiency syndrome (AIDS) treated with isoprinosine and placebo. Serum samples obtained at the commence-
ment of study and samples obtained after 24 weeks were available from 277 HIV-positive patients in the Scandina-
vian multicentre isoprinosine trial. After 24 weeks' treatment, the concentrations of ß2-microglobulin and neopterin
had increased both in the isoprinosine group and the placebo group. However, in the isoprinosine group the relative
increase within ß2-microglobulin was significantly smaller. Within neopterin, the increase from baseline level was
small and not significantly different from the change in the placebo group. The ß2-microglobulin data might reflect
a suppressive effect of isoprinosine on the HIV-induced activation of the cellular immune system. Because of the
minor changes, there is no real evidence of neopterin and ß2-microglobulin being valuable as surrogate markers in
monitoring therapy effects of isoprinosine.
Introduction
The variables available in evaluating anti-HIV treat-
ments are limited, Since wishing a reaching of conclu-
sions without waiting for survival differences to be
established, a search for surrogate markers that might
reflect therapeutic benefit early has been set up. Certain
biological markers have been applied and of these the
main part of attention has been given to the CD44- cell
count (1—4). Other biological markers include ß2-
microglobulin and neopterin, which are markers of the
activated cellular immunity (5, 6). Generalized immune
activation occurs early in human immunodeficiency
virus (HIV) infection and induces an increased pro-
duction of neopterin and ß2-microglobulin, which persist
throughout the infection (7, 8). These elevated levels
of neopterin and ß2-microglobulin might be useful in
monitoring the early in vivo efficacy of anti-HIV drugs
on asymptomatic/mildly symptomatic HIV seropositive
individuals. Only one single double-blind placebo-con-
trolled study consisting of a limited number of subjects
evaluated the effect of an anti-HIV drug on serum
neopterin and ß2-microglobulin in mildly symptomatic
HIV seropositive patients. Zidovudine reduced the im-
mune activation, and neopterin and ß2-microglobulin
appeared to be early and sensitive indicators of anti-HIV
effects (9).
In retrospect we measured the levels of neopterin and
ß2-microglobulin in 277 HIV-seropositive subjects in-
cluded in the Scandinavian placebo-controlled trial of
isoprinosine (10) in order to study the immune activa-
tion markers as early indicators of the anti-HIV effect
of isoprinosine.
The Scandinavian isoprinosine study proved clinically
beneficial on the isoprinosine-treated patients with a sig-
nificant decrease in clinical progression towards ac-
quired immunodeficiency syndrome (AIDS), while no
evidence from the effect on either the CD4+ cell count
or HIV-antigen level showed up (10, 11). As neopterin
and ßa-microglobulin are markers with a rapid turnover,
the hypothesis was, that changes in HIV activity induced
by isoprinosine treatment might be detected more
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rapidly with these sensitive markers, than by the well
known CD4 count or clinical stafe.
Methods
Data and sera were collected from medical centres in Denmark
and Sweden participating in the Scandinavian isoprinosine study
(10) which was a randomized, double-blind, placebo-controlled
multicentre trial. Originally the trial enrolled 866 HIV-positive
patients without AIDS and aged 18-75 years. The treatment
consisted of l g isoprinosine administered orally three times a
day or matching placebo after an initial clinical evaluation. In
no case side effects occurred during the treatment regimen con-
tinued for 24 weeks.
In this retrospective study, sera were collected from 19 out of 21
medical centres. Baseline serum samples and samples from week
24 were available from only 277 (139 isoprinosine, 138 placebo)
of the originally enrolled patients. The paired sera of these 277
patients were all investigated in this study. The 139 patients in the
isoprinosine group and the 138 patients in the placebo group were
comparable in the non-significant differences in terms of sex, age,
body weight, medical history within three months of study entry,
physical examination, clinical staging, general well-being accord-
ing to a visual-analogue scale, substrata according to CD4 cell
count, and median number of baseline CD4 and CD8 lymphocytes.
At baseline the isoprinosine group had a median CD4 count of 540
X 106/1 (range, 8-2100 X 106/1) and the placebo group a median
CD4 count of 510 X 106/1 (range 0-2600 X 106/1). Nine percent
of the study population (5% isoprinosine, 4% placebo) had a base-
line CD4 count below 200 X 106/1, while 40% (18% isoprinosine,
22% placebo) had a baseline CD4 count between 200-500
X 106/1, and 51% (26% isoprinosine, 25% placebo) had over 500
X 106/1. The median CD4 count in our selected group (n = 277)
was not significantly different from the median CD4 count in the
group of originally enrolled patients (n = 544) not taking part in
this study.
At study entry, 94% in the isoprinosine group and 90% in the pla-
cebo group were assigned to CDC Group II or III, and 6% in the
isoprinosine group and 10% in the placebo group were assigned to
CDC Group IV without AIDS.
Serum samples obtained at study entry (baseline) and at the end of
the treatment (week 24) were assayed for ß2-microglobulin with a
solid phase time-resolved fluoroimmunoassay (Pharmacia DELFIA
beta-2-microkit) and for neopterin with a radioimmunoassay (IM-
MUtest Neopterin, Henning Berlin GmbH).
Statistics
The MEDSTAT computer programme was used in analyzing the
data. Neopterin and ß2-microglobulin differences between the iso-
prinosine group and the placebo group were assessed by the Mann-
Whitney rank sum test. Correlations between the markers were de-
termined by Spearman rank correlation test. Differences were con-
sidered significant if p < 0.05.
Results
At study entry, the isoprinosine and placebo groups had
baseline median neopterin concentrations of 9.5 nmol/1
(range, 0.5-43.0 nmol/1) and 10.5 nmol/1 (range, 2.1-
34.0 nmol/1), respectively. At baseline, the median ß2-
microglobulin concentrations were 2.32 mg/1 (range,
0.34-10.49 mg/1) in the isoprinosine group and 2.23
mg/1 (range, 0.85-16.47 mg/1) (tab. 1) in the placebo
group. The differences in baseline levels between the
groups were not significant.
After 24 weeks of treatment the isoprinosine and pla-
cebo groups had higher median of neopterin and ß2-
microglobulin. The isoprinosine group had a median
neopterin concentration of 10.0 nmol/1 (range, 3.1-40.7
nmol/1) and the placebo group had a concentration of
11.3 nmol/1 (range, 3.6-57.2 nmol/1) (fig. 1). The
relative increase within neopterin from baseline was
not significantly different between the isoprinosine
group arid the placebo group. The median ß^micro-
globulin level increased to 2.40 mg/1 (range, 0.98-
9.90 mg/1) in the isoprinosine group and to 2.57 mg/1
(range, 1.13-18.47 mg/1) in the placebo group. The
relative increase within ß2-microglobulin from baseline
was significantly smaller in the isoprinosine group
(p < 0.05). A significant positive correlation
(p < 0.001) was observed between median neopterin
and ß2-microglobulin levels at baseline and week 24
in both HIV groups.
After treatment, the median CD4 count accounted for
510 X 106/1 (range, 5-1800 X 106/1) in the isoprinosine
group and 505 X 106/1 (range, 0-2300 X 106/1) in the
placebo group. The absolute and relative differences in
CD4 counts between the two groups were not signifi-
cant. Between the isoprinosine and placebo groups, the
difference in the number of patients whose condition
progressed from CDC Group II or to Group IV was
not significant, and the difference in the frequency of
night sweats, weightloss, temperature, chronic diar-
rhoea, oral Candida, hairy leukoplakia, herpes zoster and
herpes simplex infection was not evident.
Discussion
The purpose was to evaluate the use of neopterin and
ß2-microglobulin as early surrogate markers in monitor-
ing anti-HIV therapy in HIV-positive patients without
AIDS. Since neopterin and ß2-microglobulin are mark-
Tab. 1 The median level of serum neopterin (nmol/1) and serum
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Fig. 1 Median levels of neopterin, ß2-microglobulin and CD4
counts at the commencement of the study and after 24 weeks' treat-
ment. Solid-line: isoprinosine group, dashed-line: placebo group.
ers with a rapid turnover, we expected the changes in
HIV activity induced by isoprinosine to be reflected
rapidly with decreases in the levels of neopterin and ß2-
microglobulin.
After 24 weeks' treatment, the levels of neopterin and
ß2-microglobulin had increased from baseline in the iso-
prinosine and placebo groups. However, in the isopri-
nosine group the relative increase within ß2-microglobu-
lin was significantly smaller. Within neopterin, the
increase from baseline level was small but not signifi-
cantly different from the change in the placebo group.
Given the known strong sensitivity of the two markers
in HIV-infected patients, isoprinosine surprisingly
enough did not clearly affect neopterin and ß2-micro-
globulin. This might reflect a weak effect of isoprinosine
on the activated HIV-infected cellular immune system.
Because of the minor changes in the levels of the two
markers, there is no real evidence of ß2-microglobulin
and neopterin being valuable as surrogate markers in
monitoring the therapy effect of isoprinosine.
A limitation is, that neopterin and ß2-microglobulin
have been measured only at the commencement of the
study and after 24 weeks' treatment. How isoprinosine
affected the two markers in the early weeks of treatment
is unknown. Perhaps, the two markers changed maxi-
mally early in the trial and later returned toward the
levels in the placebo group as observed during treatment
with azidothymidine (9).
The mechanism of action of isoprinosine is not clarified.
It has been studied for several years, and its activity in
vitro and in vivo seems to be due largely to a stimulating
effect on the immune system while the antiretroviral ac-
tivity is minimal (12—17). The increased levels of
neopterin and ß2-microglobulin might reflect increased
activation of the cellular immune system probably due
to progression of HIV infection, despite isoprinosine
therapy. However, the ß2-microglobulin results indicate
that isoprinosine might have had a suppressive effect on
the activation of the cellular immune system induced by
HIV-infection. The increased levels of neopterin and ß2-
microglobulin might also reflect conditions other than
HIV-infection, such as opportunistic infections. How-
ever, the differences in the markers between the two
HIV groups do not seem to be explained by differences
in infections or other conditions, which may stimulate
neopterin and ß2-microglobulin, since the two groups
were comparable with non-significant differences in
clinical staging, medical history and physical examina-
tions.
In future, neopterin and ß2-microglobulin deserve to be
closely evaluated as surrogate markers in a placebo-con-
trolled trial with one of the new potent anti-HIV drugs
and with a large number of asymptomatic or mildly
symptomatic HIV-positive patients. An advantage of
measuring neopterin and ß2-microglobulin rather than
CD4 cell count or HIV antigen level is, that the two
markers can be accurately quantified in serum of all sub-
jects by simple and inexpensive assay techniques. In fu-
ture trials, it would be of interest to determine whether
those with the greatest activation marker response to
anti-HIV treatment have greater clinical benefit. A cor-
relation between an early effect of treatment on the im-
mune activation markers and long term clinical outcome
has not yet been reported in a controlled trial.
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